After pocketing $18.9M, Seagen's Clay Siegall could reclaim spot among best-paid biopharma CEOs

After joining the upper echelons of the biopharma industry’s top-paid CEOs in 2018, Seagen helmsman Clay Siegall, Ph.D., could reclaim a spot for 2021.

Last year, Siegall collected a little more than $18.9 million in total pay, Seagen reported in its proxy filing published this week. That’s nearly 14% more than the $16.49 million he took home in 2020, or about 26% more than the $14.52 million Siegall bagged in 2019.